Model Describing the Relationship Between Pharmacokinetics and Hematologic Toxicity of the Epirubicin-Docetaxel Regimen in Breast Cancer Patients
Marie Sandström(Uppsala University Hospital), Mats O. Karlsson(Uppsala University), Peter Nygren(Uppsala University), Henrik Lindman(Uppsala University), Jonas Bergh(Karolinska Institutet), Elisabet Lidbrink(Stockholm South General Hospital)
Cited by 76
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k